Truist Securities analyst Neal Dingmann upgrades Centennial Resource Dev (NASDAQ:CDEV) from Hold to Buy.
Raymond James Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $124
Raymond James analyst Steven Seedhouse maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and lowers the price target from $127 to $124.